TherapeuticsMD, Inc. — Director's Dealing 2021

Mar 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2021-03-04

Reporting Person: Finizio Robert G (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-04	Common Stock	X	179000	$0.2444	Acquired	18580964	Direct
2021-03-04	Common Stock	F	29964	$1.46	Disposed	18551000	Direct
2021-03-05	Common Stock	G	350000	—	Disposed	18201000	Direct
2020-02-28	Common Stock	G	300000	—	Disposed	17901000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-04	Warrants (right to buy)	$0.2444	X	179000	Disposed	2021-03-06	Common Stock (179000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2000000	Indirect

Footnotes

F1: On March 4, 2021, the reporting person exercised a warrant to purchase 179,000 shares of issuer common stock for $0.2444 per share. The reporting person paid the exercise price on a cashless basis, resulting in the issuer's withholding of 29,964 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 149,036 shares.

F2: The reported securities are owned by Robert Finizio Revocable Trust. Includes 1,004,941 shares previously reported as indirectly owned by the reporting person's Grantor-Retained Annuity Trust.

F3: The warrant vested quarterly in eight equal installments commencing June 30, 2011, becoming fully-vested on March 31, 2013.